--- title: mAbs vs. Benchmark description: "Single Cell Technology case study: a competition assay to quickly profile the hits" image: https://singlecelltechnology.com/hubfs/mAvs%20v%20Benchmark%20feature%20image.png --- # mAbs vs. Benchmark [ Case Study Cinemas ](https://singlecelltechnology.com/resources/tag/case-study-cinemas) [ Competition Assay ](https://singlecelltechnology.com/resources/tag/competition-assay) December 11, 2025 Share [mailto:?subject=mAbs%20vs.%20Benchmark&body=https://singlecelltechnology.com/resources/mabs-vs-benchmark](mailto:?subject=mAbs%20vs.%20Benchmark&body=https://singlecelltechnology.com/resources/mabs-vs-benchmark) ### The Challenge  - Seeking antibodies with similar function as a clinical benchmark Ab - Also find broadly reactive antibodies to 4 related but different protein targets - Aiming to shorten downstream timelines screening antibody hits ### The Single Cell Solution - Implement a competition assay in-line to discovery with a functional benchmark antibody - Screen all antibodies in parallel with the competition assay ### Highlights - Over 2,000 antibody hits discovered from 100M donor human PBMCs - Competition to clinical benchmark antibody determined for all hits in parallel ## Problem: Taking on the Challenge You may have a benchmark, or even a clinical-stage antibody, with a well-characterized functional profile. The next objective is to identify antibodies that compete with this benchmark for antigen engagement to quickly bin them into possible functional antibodies and likely non-functional. In this case study, human peripheral blood cells (PBMCs) from donors recently vaccinated with the seasonal influenza vaccine were comprehensively profiled using AbTheneum screening. The campaign focused on identifying antibodies that were cross-reactive to a highly diverse panel of hemagglutinin (HA) proteins and that competed with a clinical-stage, flu-neutralizing antibody, MEDI8852. ## Solution: Finding a Better Way AbTheneum combines multiple assays during each antibody campaign. After obtaining activated memory B cells from human PBMCs using a commercial kit, cells were deposited onto a picoliter device. 3 capture slides were generated to screen all antibodies for binding to 4 HA proteins and competition with MEDI8852. The 4 HA proteins from a different viral subtype were selected based on their vastly divergent sequences: - A/California/7/2009 HA, - A/Vietnam/ 1194/2004 HA, - A/California/7/2004,  - A/Shanghai/ 1/2013 HA, which are named in this work H1N1, H3N2, H5N1, and H7N9, respectively. Over 2,000 anti-HA antibody hits were discovered from 100M donor PBMCs, with 15 mAbs cross-reactive to all 4 HAs. AbTheneum screened for cross-reactivity to all 4 HA proteins and MEDI8852 competition (Figure 1). ![flu poster Fig 3](https://singlecelltechnology.com/hs-fs/hubfs/flu%20poster%20Fig%203.png?width=771&height=527&name=flu%20poster%20Fig%203.png)Figure 1. Screening plan and small cropped region from the same area on all 3 slides across 8 screening conditions. Slides were scanned on a fluorescent slide scanner and aligned across all slides and images. ### Just want the highlights? [![Download the 1-page Case Study mAbs v Benchmark Competition assay to quickly profile hits  ](https://hubspot-no-cache-na2-prod.s3.amazonaws.com/cta/default/39886626/interactive-202370299055.png) ](https://singlecelltechnology.com/hs/cta/wi/redirect?encryptedPayload=AVxigLIbN5mYehmyDy4zttdV%2F6rkmHWov15qZJBVGsGvQ9aRLgcqtPyYMA6NC1nl%2BfiyGkXKo%2BmV2hcEhPu7bXmwgmELByKh%2BwNUVFfGknydNqH%2FcBL6Y1d%2FP6h59%2BURRXumHT7zFd7X98lVeoLQsTleNvh3SHOgwRgx0eAoRTWd%2F%2BBkaxGxD2z%2BdCrXvz43iSGLCTOIzXtwWYNMcyl85ZkuZkI%3D&webInteractiveContentId=202370299055&portalId=39886626) [![Browse all Case Study Cinemas](https://hubspot-no-cache-na2-prod.s3.amazonaws.com/cta/default/39886626/interactive-206785728076.png) ](https://singlecelltechnology.com/hs/cta/wi/redirect?encryptedPayload=AVxigLKaHNS6ZQINJ59si27jYUq5MGv8z13LkG9q8SE%2BtZaxePKa9MqRYhLsQNpnH86DCKkqBTXKX73xhEpsvqa1KUhR8RG9K5ZX%2BPWe3vzd%2Bx9x8gR9R2zcpgbhiLbYvq%2BGuewLiF41C%2BIdRGlALbDc91rUsbbaJKftJdApZQOsoA6O3oHRvanGlSEz%2Bqz4SXhgLdOD%2F1aZng%3D%3D&webInteractiveContentId=206785728076&portalId=39886626) All sequences are captured in AbTheneum and sequenced by Next Generation Sequencing (NGS). 5 unique mAbs were expressed (Figure 2) with diverse binding profiles. The cross-reactivity screening results against the 4 HA proteins was 100% confirmed by ELISA. The competition assay against MEDI8852 antibody also confirmed. Ab3-009 (Fig. 2, purple) shows cross-reactivity against all 4 HA proteins in the study and competes with MEDI8852, meeting target goals. ![PEGS24 talk flu validation figure](https://singlecelltechnology.com/hs-fs/hubfs/PEGS24%20talk%20flu%20validation%20figure.jpg?width=3900&height=1511&name=PEGS24%20talk%20flu%20validation%20figure.jpg) Figure 2. Five antibodies with diverse binding profiles were expressed and tested by ELISA against all HA proteins and competition with MEDI8852. Small image cutout shows AbTheneum screening result compared to curves generated by ELISA. Negative MEDI8852 screening result means antibody blocks/competes with MEDI8852. ## Impact: What We Achieved This case study demonstrates AbTheneum enables rapid filtering from thousands of antibodies to find mAbs with rare properties. It also offers the advantage of layering multiple screens, delivering layers of data on top of the natively paired full-length sequences from human cells. The ELISA data confirmed the screening data captured by AbTheneum, showcasing the predictive power of the cross-reactivity and competition assays. ### Thinking about a similar study? [![Contact Us](https://hubspot-no-cache-na2-prod.s3.amazonaws.com/cta/default/39886626/interactive-150741137986.png) ](https://singlecelltechnology.com/hs/cta/wi/redirect?encryptedPayload=AVxigLL8mvEDbeuO80yl6oAqTNZYvRN8jsKH5J2IWZdidjJ7NNOjbw9ss532SX1lJt2%2FeWhA8xmIuJ389g%2BCI4Hk6j2laoW073fb7fK8A%2Bh2MQtpFIjpJfMaSkBZamIJLL60YxX9h8nstvUq01IwtSIY%2FNR2eMbsoIZrH7%2FTDIMRe5a4oPN6f9R9fHcxIcw%3D&webInteractiveContentId=150741137986&portalId=39886626)   ## Related Articles [![SurfScreen for membrane-bound targets](https://singlecelltechnology.com/hs-fs/hubfs/Mission-%20Possible%20feature%20image.png?width=352&name=Mission-%20Possible%20feature%20image.png) ](https://singlecelltechnology.com/resources/mission-possible) ### [Mission: Possible](https://singlecelltechnology.com/resources/mission-possible) December 12, 2025  |  The Challenge Membrane-bound targets sometimes cannot be made into recombinant protein for screening Some recombinant forms of membrane-bound targets... [![FACS plots of mouse lymph node cells](https://singlecelltechnology.com/hs-fs/hubfs/Ag%20enrichment%20featured%20image.png?width=352&name=Ag%20enrichment%20featured%20image.png) ](https://singlecelltechnology.com/resources/antigen-enrichment-for-antibody-discovery) ### [Antigen Enrichment](https://singlecelltechnology.com/resources/antigen-enrichment-for-antibody-discovery) January 21, 2025  |  The Challenge Increasing hit rates in antibody discovery campaigns The Single Cell Solution Study markers in mouse cells for antibody-secreting cells... [![SurfScreen Pilot for TIGIT](https://singlecelltechnology.com/hs-fs/hubfs/casestudy4.png?width=352&name=casestudy4.png) ](https://singlecelltechnology.com/resources/surfscreen-pilot-for-tigit) ### [SurfScreen Pilot for TIGIT](https://singlecelltechnology.com/resources/surfscreen-pilot-for-tigit) October 25, 2023  |  The Challenge Screening for antibodies against membrane targets to confirm antibody binds to native conformation of the target Can also be applied to... ```json { "@context" : "https://schema.org", "@type" : "BlogPosting", "author" : { "@type" : "Person", "name" : "Single Cell Technology", "url" : "https://singlecelltechnology.com/resources/author/single-cell-technology" }, "dateModified" : "2026-02-03T21:51:22.409Z", "datePublished" : "2025-12-11T22:46:41.000Z", "headline" : "mAbs vs. Benchmark", "image" : [ "https://singlecelltechnology.com/hubfs/mAvs%20v%20Benchmark%20feature%20image.png" ], "mainEntityOfPage" : { "@id" : "https://singlecelltechnology.com/resources/mabs-vs-benchmark", "@type" : "WebPage" }, "publisher" : { "@type" : "Organization", "logo" : { "@type" : "ImageObject", "url" : "https://singlecelltechnology.com/hubfs/Single%20Cell_Main_Logo_4C-2-1-1.png" }, "name" : "Single Cell Technology" } } ```